全文获取类型
收费全文 | 6812篇 |
免费 | 432篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 262篇 |
妇产科学 | 140篇 |
基础医学 | 753篇 |
口腔科学 | 107篇 |
临床医学 | 1467篇 |
内科学 | 1154篇 |
皮肤病学 | 61篇 |
神经病学 | 519篇 |
特种医学 | 124篇 |
外科学 | 571篇 |
综合类 | 77篇 |
一般理论 | 9篇 |
预防医学 | 869篇 |
眼科学 | 83篇 |
药学 | 351篇 |
中国医学 | 2篇 |
肿瘤学 | 661篇 |
出版年
2024年 | 4篇 |
2023年 | 34篇 |
2022年 | 35篇 |
2021年 | 125篇 |
2020年 | 80篇 |
2019年 | 95篇 |
2018年 | 149篇 |
2017年 | 107篇 |
2016年 | 122篇 |
2015年 | 138篇 |
2014年 | 224篇 |
2013年 | 330篇 |
2012年 | 490篇 |
2011年 | 575篇 |
2010年 | 304篇 |
2009年 | 270篇 |
2008年 | 491篇 |
2007年 | 564篇 |
2006年 | 525篇 |
2005年 | 543篇 |
2004年 | 500篇 |
2003年 | 454篇 |
2002年 | 468篇 |
2001年 | 42篇 |
2000年 | 29篇 |
1999年 | 65篇 |
1998年 | 57篇 |
1997年 | 57篇 |
1996年 | 49篇 |
1995年 | 42篇 |
1994年 | 45篇 |
1993年 | 30篇 |
1992年 | 30篇 |
1991年 | 24篇 |
1990年 | 15篇 |
1989年 | 11篇 |
1988年 | 9篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 10篇 |
1984年 | 20篇 |
1983年 | 10篇 |
1982年 | 18篇 |
1981年 | 11篇 |
1980年 | 19篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1971年 | 1篇 |
排序方式: 共有7255条查询结果,搜索用时 15 毫秒
61.
62.
Manukyan M Triantafilou K Triantafilou M Mackie A Nilsen N Espevik T Wiesmüller KH Ulmer AJ Heine H 《European journal of immunology》2005,35(3):911-921
Lipoproteins or lipopeptides (LP) are bacterial cell wall components detected by the innate immune system. For LP, it has been shown that TLR2 is the essential receptor in cellular activation. However, molecular mechanisms of LP recognition are not yet clear. We used a FLAG-labeled derivative of the synthetic lipopeptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,S)-propyl]-(R)-cysteinyl-seryl-(lysyl)(3)-lysine (Pam(3)CSK(4)) to study the roles of CD14, TLR2 and TLR1 in binding and signaling of LP and their molecular interactions in human cells. The activity of Pam(3)CSK(4)-FLAG was TLR2 dependent, whereas the binding was enabled by CD14, as evaluated by flow cytometry and confocal microscopy. Using FRET and FRAP imaging techniques to study molecular associations, we could show that after Pam(3)CSK(4)-FLAG binding, CD14 and Pam(3)CSK(4)-FLAG associate with TLR2 and TLR1, and TLR2 is targeted to a low-mobility complex. Thus, LP binding to CD14 is the first step in the LP recognition, inducing physical proximity of CD14 and LP with TLR2/TLR1 and formation of the TLR2 signaling complex. 相似文献
63.
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant 总被引:5,自引:0,他引:5
McNeel DG Knutson KL Schiffman K Davis DR Caron D Disis ML 《Journal of clinical immunology》2003,23(1):62-72
A pilot vaccine study was conducted to test the safety and immunological efficacy of four monthly immunizations of an MHC class I peptide vaccine, the E75 HLA-A2 epitope from HER-2/neu, using flt3 ligand as a systemic vaccine adjuvant. Twenty HLA-A2-expressing subjects with advanced stage prostate cancer were randomly assigned to one of four immunization or treatment schedules: (a) Flt3 ligand (20 g/kg per day) administered subcutaneously daily for 14 days on a 28-day cycle, monthly for four months; (b) flt3 ligand course as above with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle; (c) flt3 ligand course as above with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle; or (d) E75 peptide admixed with granulocyte–macrophage colony-stimulating factor and administered intradermally once every 28 days, as has previously been reported. The primary endpoints of the study were the determination of safety and immunological efficacy in generating E75-specific T cells as determined by peptide-specific interferon-gamma ELIspot. Adverse events included one grade 3 skin reaction and the development of grade 2 autoimmune hypothyroidism in two subjects with preexisting subclinical autoimmune hypothyroidism. Dendritic cells were markedly increased in the peripheral blood of subjects receiving flt3 ligand with each repetitive cycle, but augmentation of antigen-presenting cells within the dermis was not observed. Apart from a single subject, no significant peptide-specific T-cell responses were detected by ELIspot, whereas delayed-type hypersensitivity responses were detectable in control subjects and in subjects receiving peptide vaccine early in the course of flt3 ligand administration. The absence of robust peripheral immune responses in the current study may be attributable to the small numbers of subjects or differences in the subject population. In addition, the inability of flt3 ligand to augment the number of peripheral skin antigen-presenting cells may have contributed to the absence of robust peptide-specific immunity detectable in the peripheral blood of immunized subjects treated with flt3 ligand. 相似文献
64.
Grummer-Strawn LM Rice SP Dugas K Clark LD Benton-Davis S 《Maternal and child health journal》1997,1(1):35-42
Objective: This study evaluates the effectiveness of a peer counseling program at increasing breastfeeding by participants in the Mississippi Special Supplemental Nutrition Program for Women, Infants and Children (WIC). Methods: Data from the 1989–1993 Pediatric Nutrition Surveillance System were analyzed to compare breastfeeding rates in clinics with and without peer counseling programs. A questionnaire completed by program staff to describe the program in greater detail helped identify characteristics associated with greater success. Results: The incidence of breastfeeding rose from 12.3% to 19.9% in those clinics with peer counseling programs, but only from 9.2% to 10.7% in clinics without a program. Clinics that started a program earlier showed greater changes in breastfeeding incidence. However, the presence of lactation specialists or consultants in the clinic appeared to be more important than the presence of less-trained peer counselors. Peer counselors who spent more than 45 minutes per participant were more effective than those spending less time. Conclusions: The peer counseling program significantly increased the incidence of breastfeeding, particularly in clinics with lactation specialists and consultants. Success can be enhanced by ensuring that peer counselors spend a great deal of time with the participants. 相似文献
65.
The effectiveness of an antiarrhythmic drug is judged by the degree of ventricular arrhythmia suppressed by the drug. It has been suggested that a certain degree of ventricular arrhythmia suppression should be targeted to prove efficacy. Targets used to define the effectiveness of an antiarrhythmic agent included an 80% reduction in the ventricular premature complexes (VPCs) and 90% suppression of nonsustained ventricular tachycardia (NVT) episodes or complete abolition of runs of sustained VT (SVT) [1]. Other dose-adjusted antiarrhythmic trials have attempted to achieve either isolated control of the PVCs of greater-than-or-equal70% [2--5] with the suppression of the high grades of arrhythmia such as couplets and NVT of >90% and 100%, respectively [2, 3]. Such targets of arrhythmia suppression were recommended to avoid errors encountered with the occurrence of the spontaneous variability of ventricular arrhythmia and to be confident that antiarrhythmic therapy has produced a true drug effect [6]. Presently, there is no evidence that suppression of these arrhythmias with type I antiarrhythmic drugs is likely to reduce sudden death [4, 6]. The survival of patients with frequent VPCs and high-grade forms (couplets [C], NVT) and organic heart disease is not dependent on the degree of arrhythmia suppression. The survival of patients with low LVEF of <40% and runs of NVT is improved and is similar to that of patients with good LVEF of greater-than-or-equal40%. Such a lack of correlation between arrhythmia suppression and survival might be a unique feature of the antifibrillatory drugs and might not be applied to the antiectopic drugs. If a high degree of arrhythmia suppression is not needed, lower targets of suppression may be necessary. Lower drug dosages may improve the risk--benefit ratio of antiarrhythmic treatment. 相似文献
66.
67.
68.
The effectiveness of an antiarrhythmic drug is judged by the degree of ventricular arrhythmia (VA) suppression. We evaluated the relationship between the degree of VA suppression and survival in a dose-adjusted trial of 110 symptomatic patients treated with amiodarone. Cohorts had left-ventricular ejection fraction (LVEF) of 41 plus minus 18%, ventricular premature contractions (VPCs) of 445 plus minus 571 h, couplets (C) of 733 plus minus 1498 24 h and nonsustained (N) ventricular tachycardia (VT) of 65 plus minus 217 24 h; these conditions were followed for 15 plus minus 11.5 months. Amiodarone was initiated with an oral loading of 670 plus minus 111.7 mg per day for 10 days and continued on maintenance of 274.9 plus minus 102 mg per day. Survival rates of responders and nonresponders with VPCs <70%, 70--89%, greater-than-or-equal90%; C greater-than-or-equal 90%; NVT (100%); and the response to all 3 criteria (suppresion of VPCs greater-than-or-equal70%, C greater-than-or-equal 90% and complete abolition of NVT) were not statistically significant. Survival rates as a function of LVEF <40% (51 patients) or greater-than-or-equal40% (59 patients), as well as responders or nonresponders to all three criteria, were not significant (p = NS). We conclude that, in patients treated with low-dose amiodarone, the degree of VA suppression of PVCs, C and NVT does not predict survival; the survival of patients with LVEF <40% improved irrespective of VA suppression; and criteria for VA suppression should be reassessed at lower levels of suppression for the improvement of the drug risk:benefit ratio. More improvement is not necessarily better. 相似文献
69.
Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. 总被引:4,自引:0,他引:4
Charles Given Barbara Given Mohammad Rahbar Sangchoon Jeon Ruth McCorkle Bernadine Cimprich Andrzej Galecki Sharon Kozachik Albert Brady Mary Jo Fisher-Malloy Kathy Courtney Elizabeth Bowie 《Journal of clinical oncology》2004,22(3):507-516
PURPOSE: To describe a randomized trial of a cognitive behavioral intervention on reducing symptom severity among patients diagnosed with solid tumors and undergoing a first course of chemotherapy and to determine whether the intervention had an additive or interactive effect on symptom severity in the presence of supportive care medications. PATIENTS AND METHODS: Patients (N = 237) were accrued from comprehensive and community cancer centers, interviewed, and randomly assigned to either the experimental intervention (n = 118) or conventional care (n = 119). A symptom severity index, based on summed severity scores across 15 symptoms, was the primary outcome. Each patient's site of cancer, stage at diagnosis, chemotherapy protocols, and use of supportive medications were learned from medical records. RESULTS: Groups were equivalent at baseline, and attrition by characteristics by group was not different. The proportion of patients not receiving chemotherapy at 10 and 20 weeks did not differ by group. At the 10- and 20-week observations, there was a significant interaction between the experimental group and baseline symptom severity. Patients in the experimental group who entered the trial with higher symptom severity reported significantly lower severity at 10 and 20 weeks. Controlling for chemotherapy treatment status at follow-up and supportive care medications did not alter the effect of the experimental intervention. CONCLUSION: Compared with conventional care alone, the experimental intervention was effective among patients who entered the trial with higher levels of symptom severity. Age, sex, site or stage of cancer, and supportive medications did not modify the effect of this cognitive behavioral intervention on symptom severity. 相似文献
70.
Association of markers of insulin and glucose control with subsequent colorectal cancer risk. 总被引:2,自引:0,他引:2
Sharon H Saydah Elizabeth A Platz Nader Rifai Michael N Pollak Frederick L Brancati Kathy J Helzlsouer 《Cancer epidemiology, biomarkers & prevention》2003,12(5):412-418
We evaluated the association of plasma insulin and other markers of insulin and glucose control with subsequent colorectal cancer. Incident colon (n = 132) and rectal (n = 41) cancer cases and matched controls (n = 346) were identified between baseline in 1989 and 2000 among participants in a community-based cohort in Washington County, Maryland. Circulating markers of insulin and glucose control were measured in baseline blood samples. Body mass index (BMI) and use of medications to treat diabetes mellitus were self-reported at baseline. Conditional logistic regression was used to estimate matched odds ratios (ORs). Compared with the lowest fourth, participants with insulin concentrations in the highest fourth were not at an increased risk of colorectal cancer [OR, 0.78; 95% confidence interval (CI), 0.45-1.35; P(trend) = 0.24]. Similarly, no associations were observed for the ratio of total cholesterol:HDL-cholesterol, triglycerides, and insulin-like growth factor binding protein 1. However, those in the highest fourth of glycosylated hemoglobin (HbA(1c)) level had a slightly increased risk of colorectal cancer (OR, 1.57; 95% CI, 0.94-2.60; P(trend) = 0.02). The OR of colorectal cancer was 1.70 (95% CI, 1.01-2.86; P(trend) = 0.08) comparing BMI >/=30 kg/m(2) to <25 kg/m(2). The OR of colorectal cancer was 2.43 (95% CI, 1.10-5.38) for the use of medications to treat diabetes. The associations of higher HbA(1c), higher BMI, and the use of medications to treat diabetes, with colorectal cancer lend support to the hypothesis that perturbations in insulin and glucose control may influence colorectal carcinogenesis. It is possible that HbA(1c), BMI, and the use of medications to treat diabetes, as a surrogate for protracted or severe type 2 diabetes mellitus, may have been better time-averaged indicators of hyperinsulinemia and hyperglycemia than the plasma markers that were measured once prediagnostically in a nonfasting population. 相似文献